M
Medyria
Blood-flow velocity sensors and catheters for coronary diagnostics
About Medyria
Medyria is a Swiss medtech company at Technopark Winterthur developing blood-flow velocity sensors and catheter technologies for invasive coronary diagnostics. Its lead product PyCath is a sensor-equipped microcatheter that measures blood flow velocity during interventional cardiology procedures, aiming to reduce X-ray exposure and contrast use. Founded in 2012 and led by CEO Mauro M. Sette, Medyria raised CHF 3.5 million in July 2026 to fund FDA 510(k) clearance and a US commercial launch for PyCath, following a CHF 1.5 million round a year earlier. Sources: Startupticker 24 Jul 2026; Venture Leaders.
Source: Dealroom company dataAt a glance
- Founded
- 2014
- Headquarters
- Zurich, Switzerland
- Sector
- Biotech & Life Sciences
Knowledge graph
More headlines
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A9 investors entered at this stage
Fongit Seed Invest
Verve Ventures
ZKB - Zürcher Kantonalbank
FONGIT
3wventures
Yellowstone Holding
Efficient Frontier Invest
StartAngels
EFI Lake Geneva Ventures
Series B and later1 investor entered at this stage
Buenavista Equity Partners
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Medyria on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Medyria on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.